Imaging3 Inc., a development stage medical device company, provides a portable proprietary imaging technology designed to produce 3D x-ray images in real time.
The last earnings update was 34 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Imaging3 is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Imaging3 has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Imaging3. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Imaging3's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Imaging3 has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Imaging3's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Imaging3's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Imaging3's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Imaging3 is high growth as no earnings estimate data is available.
Unable to determine if Imaging3 is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Imaging3's filings and announcements here.
Imaging3's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. John B. Hollister, MBA has been Chief Executive Officer of Imaging3, Inc. since December 19, 2017 and served as its Chairman since December 19, 2017. Mr. Hollister served as a Director of Imaging3, Inc. since December 2017. He served as Chief Executive Officer of NuLife Sciences, Inc. Mr. Hollister served as Interim Chief Executive Officer of Northsight Capital, Inc. since October 21, 2015 until November 13, 2016. Mr. Hollister served as the Chief Executive Officer of Nemus Bioscience Inc. from 2014 to August 24, 2015. Mr. Hollister served as the Senior Vice President of Marketing at Tethys Bioscience, Inc. He served as Chief Executive Officer of EEG Spectrum International. He served as a Director and Global Commercial Leader in Oncology at Amgen. Prior to Amgen, Mr. Hollister started his pharmaceutical career at SmithKline Beecham. He has a strong working knowledge of all facets of product development and commercialization. Mr. Hollister has more than 25 years of commercial leadership in the pharmaceutical, biotech and medical device fields, including GlaxoSmithKline and Amgen. He has extensive experience in all aspects of commercialization in the healthcare industry. He served as a Director of Northsight Capital, Inc. since August 13, 2014. He served as a Director of Nemus Bioscience Inc. from 2014 to August 24, 2015. He is experienced in both domestic and international marketing, the direction of multiple product launches and general management. He is a long-standing board member for the leading charity in mental health research, the Brain and Behavior Research Foundation. He received his BA in Economics from Stanford University and his MBA from the Drucker Management Center at the Claremont Graduate University.
John's compensation has been consistent with company performance over the past year.
John's remuneration is lower than average for companies of similar size in United States of America.
Chief Executive Officer
Executive VP & CFO
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Imaging3 board of directors is less than 3 years, this suggests a new board.
Imaging3 Inc., a development stage medical device company, provides a portable proprietary imaging technology designed to produce 3D x-ray images in real time. The company’s lead device, the Dominion Smartscan, is a patented fluoroscopic imaging device that can produce real-time 2D, 3D, and CT-like slice-through images in one second of imaging time and without the radiation. Its primary focus is on applications for the healthcare industry, including human and veterinary, as well as for non-healthcare related applications, such as agricultural and industrial parts inspection and security screening. The company was formerly known as Imaging Services, Inc. and changed its name to Imaging3, Inc. in August 2002. Imaging3, Inc. was founded in 1993 and is based in Encino, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.